Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01683955 · ClinicalTrials.gov registry record · Phase 1

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

A Phase 1 study, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 1
Development phase
139
Enrollment target

NCT01683955 is a Phase 1 study that has completed, run by Henry Ford Health System. The registered enrollment target is 139 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01683955, a Phase 1 study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 1
Development phase
139 participants
Enrollment target

Study Summary

This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

Interventions

  • DRUG Placebo
  • DRUG Tranexamic acid

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2013-01-01
Est. Completion 2013-11-03
Phase Phase 1

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT01683955

The ClinicalTrials.gov registry entry for NCT01683955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01683955 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01683955 about?

NCT01683955 is a clinical study titled "Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty". This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

What is the current status of trial NCT01683955?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2013-01-01. Estimated completion is 2013-11-03.

What interventions are being tested in trial NCT01683955?

The interventions under investigation include: Placebo (DRUG), Tranexamic acid (DRUG).

Who is sponsoring clinical trial NCT01683955?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.